@WBA
Even fund managers get it wrong
Just have to look at Afterpay.......all of them said this was a bubble waiting to happen @$60
What share price now.....$150+
They failed miserably
In regards to Starpharma being the next CSL.....possibly if it doesn't get taken over
I posted this some time ago......thought it was worth another read
DEP™Docetaxel/Irinotecan/Cabazitaxel are worth billions and billions to Starpharma
You just need to look at the less potent molecules without the Starpharma's Drug Enhanced Product (DEP™
to appreciate this
Below are some figures.......which I have posted many times before.......just in case some of the new holders do not know this
Currently there are
85 clinical trials being conducted globally using
docetaxel
Currently there are
322 clinical trials being conducted globally using
irinotecan
Currently there are
35 clinical trials being conducted globally using
cabazitaxel
That's a lot of trials and if they go through to phase 3.......can you imagine how much money is being flushed down the toilet (my opinion of course)
Why would anyone do trials with these drugs and not use DEP™ technology of Starpharma
It just does not make sense (hundreds and hundreds of millions of dollars being wasted - my opinion of course)
Oh well "Ce La Vie"
So let us see how much revenue these 3 drugs.......docetaxel, irinotecan, and cabazitaxel bring in for the big Pharma's
Docetaxel (Taxotere ®
peak sales ~US$3.1B
Cabazitaxel (Jevtana ®
sales were ~US$400M in 2016
Irinotecan (Camptosar®
peak sales ~US$1.1B
That is a total of US$4.6 billion which when you translate it into AUD$.........(exchange rate .71).........AUD$6.47 billion
Think of these above as revenue annually.........not bad at all
As we all know these DEP ® cancer drugs are in various stages of clinical trials
DEP ® DOCETAXEL PHASE 2 - to be completed this year (and monetised under a license agreement with royalties....if not beforehand for the equivalent of AUD422 million)
DEP ® IRINOTECAN PHASE 2 - to be completed this year..........
DEP ® CABAZITAXEL PHASE 2 - to be completed thiscalendar year
As this document below is subject to copyright, I have elected to post the link. Definitely worth a read......and you can find many more articles by searching
https://www.pfizer.com/files/research/research_clinical_trials/ethics_committee_guide.pdf[/BCOLOR]
In conclusion........ Starpharma patent portfolio currently has around 15 active patent families with over 120 granted patents and more than 30 patent applications pending.
As Jackie likes to put it
SO MUCH OPTIONALITY
I look forward to a company changing calendar year. With all the information out there........how can Starpharma be at this ridiculously low value. I mean with just the 3 in house drugs being developed......how many billion was mentioned
(20min delay)